Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report

Cancer stem cells in breast cancer migrating to the bone marrow may cause future metastasis, particularly during periods of decreased immunity. Natural killer (NK) cells have a role in immune surveillance and are able to target cancer stem cells. The present study reported a case in which NK cell-ba...

Full description

Saved in:
Bibliographic Details
Published inMolecular and clinical oncology Vol. 7; no. 3; pp. 493 - 497
Main Authors Chidambaram, Ranganathan, Terunuma, Hiroshi, Balamurugan, Madasamy, Dedeepiya, Vidyasagar Devaprasad, Sumana, Premkumar, Senthilkumar, Rajappa, Rajmohan, Mathaiyan, Karthick, Ramalingam, Preethy, Senthilkumar, Abraham, Samuel J.K
Format Journal Article
LanguageEnglish
Published England D.A. Spandidos 01.09.2017
Spandidos Publications
Spandidos Publications UK Ltd
Subjects
autologous immune enhancement therapy
Bone marrow
Breast cancer
cancer stem cells
Cancer therapies
Care and treatment
Case reports
Case studies
Chemotherapy
Cytotoxicity
Diagnosis
immune loopholes
Immune system
Immunotherapy
Lymphatic system
Mastectomy
Medical prognosis
Metastasis
natural killer cells
Patients
Radiation therapy
Stem cells
Studies
Surgery
Tomography
natural killer cells
breast cancer
immune loopholes
cancer stem cells
autologous immune enhancement therapy
Online AccessGet full text

Cover

More Information
Summary:Cancer stem cells in breast cancer migrating to the bone marrow may cause future metastasis, particularly during periods of decreased immunity. Natural killer (NK) cells have a role in immune surveillance and are able to target cancer stem cells. The present study reported a case in which NK cell-based autologous immune enhancement therapy was used combined with conventional treatments in a patient with stage IIIA breast cancer, yielding >28 months of disease-free survival. However, there was a gradual decline in the in vitro expansion of NK cells with subsequent chemotherapeutic treatments. As this NK cell decline following chemotherapy may contribute to cancer cell immune evasion and future metastasis; modifying current cancer therapies in order to avoid potentially compromising the immune system may lead to improved treatment outcomes.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2017.1333